Natera growth playbook

Write a unique title and description for every Signatera, Latitude, Altera and Empower page from one template: cancer type, the setting (after surgery, during treatment, surveillance), the patient or clinician audience, and the Medicare coverage line where it applies. Fix the cervical heading. Make the hub and FAQ describe Signatera across solid tumors, not colorectal only. Add a pre-publish check so a new indication page cannot go live with a borrowed description.

Search snippets are the first message most patients and clinicians see. Correct, specific snippets lift click-through and stop wrong-disease text from being repeated by AI assistants, at almost no cost.

[ ] Pancreatic (patient + clinician): remove "anal cancer"
[ ] Liver (patient + clinician)
[ ] Gastroesophageal (patient + clinician)
[ ] Bile duct (patient + clinician)
[ ] Signatera hub, patient overview, FAQ: describe all solid tumors
[ ] Cervical patient page: heading says Pancreatic
[ ] 15 pages with no description
[ ] CMS rule: no duplicate descriptions

• Review slows the fix

  Send the 11 wrong snippets first as corrections, the 15 empty ones next.

• Search engines rewrite snippets anyway

  Accurate on-page text makes the rewrite accurate too.

• Your websiteSignatera page snippets (checked October 21, 2026): eight pages (the pancreatic, liver, gastroesophageal and bile duct cancer pages, patient and clinician versions) share the meta description "Signatera(TM) is a powerful, personalized assay that provides accurate monitoring for anal cancer recurrence"; the main Signatera page, the patient overview and the FAQ all describe Signatera as "a sensitive ctDNA test for colorectal cancer"; the cervical cancer patient page's main heading reads "Signatera(TM) for Pancreatic Cancer".Source
• Your websiteFifteen oncology pages in the sitemap have no meta description at all, including the oncology hub, Signatera for sarcoma, ovarian, head and neck and skin cancers (patient and clinician pages), Signatera CDx, Signatera Genome, Signatera in lymphoma and both Latitude pages; several titles are generic, such as "Signatera for Sarcoma | Natera".Source
• HiringOncology field build-out: on October 14, 2026 Natera posted Clinical Oncology Specialist, GU roles for Washington DC, Detroit/Indianapolis, Pittsburgh, Denver/Phoenix and Orlando plus two Regional Directors, GU Oncology Sales (East and West); on October 19 three Clinical Oncology Specialist, Breast roles (Dallas/Fort Worth, Ohio/Kentucky, Philadelphia/South Jersey); and a Sales Training Manager, Oncology on October 12. Of 230 open roles, Oncology Sales is the largest department (44).Source
• HiringSenior Director / Director, Breast Oncology Lifecycle Management (posted October 8, 2026): will "Define value proposition and messaging framework in collaboration with commercial marketing for Natera's oncology suite of products in breast cancer", build "a roadmap to fill evidence data gaps", develop KOL engagement plans and support Medicare/MolDx and commercial payer dossiers for non-covered indications.Source

Pass the page's cancer type and audience (patient or clinician) as hidden fields, ask clinicians for practice ZIP, and route clinician leads to the territory's oncology specialist and patient leads to patient support. Report response time and conversion by indication.

A lead that arrives tagged with its cancer type and territory reaches the right specialist the same day, and marketing finally sees which pages create orders.

• Patient data in a sales tool

  Keep patient leads out of the sales queue and follow privacy policy.

• HiringSenior Product Manager, Sales, Marketing & Business Solutions (remote US, posted October 13, 2026): owns "the tools for generating demand, managing accounts and pipeline, and running campaigns"; "Salesforce is the center of this portfolio today, and the scope is growing to include marketing automation"; will "Manage the integration points between CRM and marketing automation, including lead lifecycle, scoring, routing, and attribution" and bring "order to a loosely governed portfolio". Eloqua experience is a plus.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• HiringOncology field build-out: on October 14, 2026 Natera posted Clinical Oncology Specialist, GU roles for Washington DC, Detroit/Indianapolis, Pittsburgh, Denver/Phoenix and Orlando plus two Regional Directors, GU Oncology Sales (East and West); on October 19 three Clinical Oncology Specialist, Breast roles (Dallas/Fort Worth, Ohio/Kentucky, Philadelphia/South Jersey); and a Sales Training Manager, Oncology on October 12. Of 230 open roles, Oncology Sales is the largest department (44).Source

Add an online estimate request and a payment-plan section to the oncology billing page and to each Signatera patient page, with a plain explanation of how repeat tests are billed.

Cost worry is a common reason patients hesitate; a self-serve estimate removes a phone call from the decision.

• Estimates differ from the final bill

  State the assumptions on every estimate.

• Your websiteBilling: the women's health pricing page offers a personalized cost estimate (Panorama, Horizon, Empower, Vistara), financial assistance at "$0 to $239 per test", and interest-free payment plans of up to 12 months, and says "over 60% of patients have no out-of-pocket cost with insurance". The oncology billing page lists Signatera's Medicare indications and a phone number and email for financial assistance, but has no online cost estimate request and no payment-plan details.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source

Turn the page into a printable, setting-by-setting question guide a patient brings to an appointment, with the coverage line for her stage, and a matching one-pager for breast oncologists. Track downloads and form submissions by setting.

Patients who arrive with specific questions start the conversation the specialist would otherwise have to start.

• Seen as promotional pressure

  Keep it educational and balanced.

• HiringSenior Director / Director, Breast Oncology Lifecycle Management (posted October 8, 2026): will "Define value proposition and messaging framework in collaboration with commercial marketing for Natera's oncology suite of products in breast cancer", build "a roadmap to fill evidence data gaps", develop KOL engagement plans and support Medicare/MolDx and commercial payer dossiers for non-covered indications.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• Your websiteBilling: the women's health pricing page offers a personalized cost estimate (Panorama, Horizon, Empower, Vistara), financial assistance at "$0 to $239 per test", and interest-free payment plans of up to 12 months, and says "over 60% of patients have no out-of-pocket cost with insurance". The oncology billing page lists Signatera's Medicare indications and a phone number and email for financial assistance, but has no online cost estimate request and no payment-plan details.Source

Send the news to clinician segments by specialty (GI, breast, GU, lung), each linking to its own indication page, and test the subject line (award vs data) and call to action (read data vs order kit). Record the results as the first entries in the testing log.

Segment-specific emails beat a single newsletter, and starting the log with a strong story makes the test results meaningful.

• Review delays lose timeliness

  Pre-approve a news template.

• HiringEmail Marketing Specialist (temporary, remote US, posted October 15, 2026): runs "newsletters, GTM initiatives, and lifecycle/triggered automations", maintains "audience segmentation and automated workflows" and will "develop a testing roadmap to optimize subject lines, CTAs, and layouts", reporting on open rates, CTR and conversions.Source
• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source
• HiringOncology field build-out: on October 14, 2026 Natera posted Clinical Oncology Specialist, GU roles for Washington DC, Detroit/Indianapolis, Pittsburgh, Denver/Phoenix and Orlando plus two Regional Directors, GU Oncology Sales (East and West); on October 19 three Clinical Oncology Specialist, Breast roles (Dallas/Fort Worth, Ohio/Kentucky, Philadelphia/South Jersey); and a Sales Training Manager, Oncology on October 12. Of 230 open roles, Oncology Sales is the largest department (44).Source

Serve the hero text without waiting for scripts, reserve space for images and the news cards, and defer non-essential tags. Re-test monthly.

Clinicians open the site on phones between patients; keeping it fast protects every campaign landing there.

• Tag removal breaks tracking

  Test analytics after each change.

• Google PageSpeedHomepage on mobile: performance 60/100 (desktop 89); in the lab the hero text "Protect Health and Inform Earlier" takes 9.8s to appear on mobile (1.8s on desktop). Real visitors pass Core Web Vitals (Chrome UX Report: LCP 1.36s, INP 85ms, CLS 0.09, close to the 0.1 limit).Source

With patient consent, send triggered messages at each step: kit and tissue status, what the first result means, when the next draw is due, mobile phlebotomy options and billing help. Give practices a matching due-list email. Measure on-time repeat draws.

Reminders tied to the care plan help patients follow what their doctor ordered and make serial testing the default.

• Patient privacy

  Send only with authorization and keep results out of email.

• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• HiringEmail Marketing Specialist (temporary, remote US, posted October 15, 2026): runs "newsletters, GTM initiatives, and lifecycle/triggered automations", maintains "audience segmentation and automated workflows" and will "develop a testing roadmap to optimize subject lines, CTAs, and layouts", reporting on open rates, CTR and conversions.Source
• HiringDigital Product Manager, Tissue Acquisition Experience (posted October 20, 2026): owns the end-to-end tissue acquisition journey for "patients, clinics, pathology labs and operation teams", building software "reducing time and effort for tissue collection to support the growth of Natera's Signatera testing".Source

Translate the patient overview and the colorectal and breast patient pages with medical review, add a Spanish expert form routed to bilingual staff, and link them with hreflang. Add the next indications as demand shows.

Spanish-speaking patients and caregivers can then research the test they were offered in their own language, and the bilingual navigation service has a front door.

• Translation errors in medical text

  Use medical translators and clinical review.

• HiringOncology Trial Navigator (posted October 20, 2026): connects "Signatera patients to life-changing clinical trial opportunities" using "Natera's AI-enabled trial matching platform", piloting a navigation service to "scale this function across the oncology domain"; "Bilingual proficiency in English and Spanish preferred".Source
• Your websiteSpanish content: the sitemap has three Spanish pages (two privacy notices and the genetic information sessions page); the Panorama patient page offers a Spanish overview video; no Signatera, Altera or Empower page has a Spanish version.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source

Show each order's tissue step (requested, at pathology, received, test built) to the ordering clinic in the portal and to the patient by text, with a one-click request to the pathology lab when it stalls.

Visibility removes status calls and shortens the slowest step in the Signatera funnel.

• Status data is incomplete

  Start with the steps that are tracked reliably.

• HiringDigital Product Manager, Tissue Acquisition Experience (posted October 20, 2026): owns the end-to-end tissue acquisition journey for "patients, clinics, pathology labs and operation teams", building software "reducing time and effort for tissue collection to support the growth of Natera's Signatera testing".Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source

Define common lifecycle stages from first touch to first order and repeat order, a scoring model per business unit, and a shared attribution report, so campaigns, events and field activity are compared on orders, not opens.

A shared model lets leaders move budget to what creates orders and shows where cross-unit accounts are growing.

• Units resist common stages

  Share stages, keep unit-specific scoring.

• HiringSenior Product Manager, Sales, Marketing & Business Solutions (remote US, posted October 13, 2026): owns "the tools for generating demand, managing accounts and pipeline, and running campaigns"; "Salesforce is the center of this portfolio today, and the scope is growing to include marketing automation"; will "Manage the integration points between CRM and marketing automation, including lead lifecycle, scoring, routing, and attribution" and bring "order to a loosely governed portfolio". Eloqua experience is a plus.Source
• HiringEnterprise Strategic Accounts Manager (Chicago/Milwaukee/Madison, posted October 19, 2026): works across "Women's Health, Organ Health, Oncology, and Rare Disease" with hospital systems and IDNs on "electronic medical record (EMR) integrations, strategic contracting", and workflow standardization.Source
• HiringEmail Marketing Specialist (temporary, remote US, posted October 15, 2026): runs "newsletters, GTM initiatives, and lifecycle/triggered automations", maintains "audience segmentation and automated workflows" and will "develop a testing roadmap to optimize subject lines, CTAs, and layouts", reporting on open rates, CTR and conversions.Source

Build a GU hub (bladder, kidney, testicular, prostate where applicable) for urologists and oncologists, with evidence per setting, coverage, ordering steps and a territory-tagged contact. Pair it with an email series and local dinners in the new territories.

New reps ramp faster when marketing gives them a destination and a reason to call.

• Off-label promotion

  Keep each claim to covered and published settings.

• HiringOncology field build-out: on October 14, 2026 Natera posted Clinical Oncology Specialist, GU roles for Washington DC, Detroit/Indianapolis, Pittsburgh, Denver/Phoenix and Orlando plus two Regional Directors, GU Oncology Sales (East and West); on October 19 three Clinical Oncology Specialist, Breast roles (Dallas/Fort Worth, Ohio/Kentucky, Philadelphia/South Jersey); and a Sales Training Manager, Oncology on October 12. Of 230 open roles, Oncology Sales is the largest department (44).Source
• Your websiteSignatera page snippets (checked October 21, 2026): eight pages (the pancreatic, liver, gastroesophageal and bile duct cancer pages, patient and clinician versions) share the meta description "Signatera(TM) is a powerful, personalized assay that provides accurate monitoring for anal cancer recurrence"; the main Signatera page, the patient overview and the FAQ all describe Signatera as "a sensitive ctDNA test for colorectal cancer"; the cervical cancer patient page's main heading reads "Signatera(TM) for Pancreatic Cancer".Source
• Your websiteBilling: the women's health pricing page offers a personalized cost estimate (Panorama, Horizon, Empower, Vistara), financial assistance at "$0 to $239 per test", and interest-free payment plans of up to 12 months, and says "over 60% of patients have no out-of-pocket cost with insurance". The oncology billing page lists Signatera's Medicare indications and a phone number and email for financial assistance, but has no online cost estimate request and no payment-plan details.Source

Publish a breast hub that lists studies by setting (neoadjuvant, adjuvant, surveillance) and subtype, states coverage, and marks open questions with the trials addressing them. Update after each congress.

Clear evidence by setting supports adoption and gives payers and KOLs one reference.

• Summaries go stale

  Date each entry.

• HiringSenior Director / Director, Breast Oncology Lifecycle Management (posted October 8, 2026): will "Define value proposition and messaging framework in collaboration with commercial marketing for Natera's oncology suite of products in breast cancer", build "a roadmap to fill evidence data gaps", develop KOL engagement plans and support Medicare/MolDx and commercial payer dossiers for non-covered indications.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source

Publish three case studies with partner systems: ordering time before and after integration, standardized order sets, and outcomes such as repeat-testing adherence. Use them in enterprise pitches.

Health systems buy on peer results, and integration is easier to sell with numbers.

• Systems decline naming

  Offer anonymized versions.

• HiringEnterprise Strategic Accounts Manager (Chicago/Milwaukee/Madison, posted October 19, 2026): works across "Women's Health, Organ Health, Oncology, and Rare Disease" with hospital systems and IDNs on "electronic medical record (EMR) integrations, strategic contracting", and workflow standardization.Source
• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source

Once the pilot is ready, add a short section to the patient and clinician pages explaining trial matching, who is eligible, and how consent works, and track referrals that start from the pages.

A visible extra benefit raises the value of each test and builds goodwill with research sites.

• Raising false hope

  State eligibility limits clearly.

• HiringOncology Trial Navigator (posted October 20, 2026): connects "Signatera patients to life-changing clinical trial opportunities" using "Natera's AI-enabled trial matching platform", piloting a navigation service to "scale this function across the oncology domain"; "Bilingual proficiency in English and Spanish preferred".Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source

Turn each indication page into a 15-minute course with a quiz, use it in onboarding, and feed questions reps cannot answer back into the pages.

Faster ramp for new hires, and the website improves from the field's questions.

• Courses drift from pages

  Update both together.

• HiringOncology field build-out: on October 14, 2026 Natera posted Clinical Oncology Specialist, GU roles for Washington DC, Detroit/Indianapolis, Pittsburgh, Denver/Phoenix and Orlando plus two Regional Directors, GU Oncology Sales (East and West); on October 19 three Clinical Oncology Specialist, Breast roles (Dallas/Fort Worth, Ohio/Kentucky, Philadelphia/South Jersey); and a Sales Training Manager, Oncology on October 12. Of 230 open roles, Oncology Sales is the largest department (44).Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• Your websiteSignatera page snippets (checked October 21, 2026): eight pages (the pancreatic, liver, gastroesophageal and bile duct cancer pages, patient and clinician versions) share the meta description "Signatera(TM) is a powerful, personalized assay that provides accurate monitoring for anal cancer recurrence"; the main Signatera page, the patient overview and the FAQ all describe Signatera as "a sensitive ctDNA test for colorectal cancer"; the cervical cancer patient page's main heading reads "Signatera(TM) for Pancreatic Cancer".Source

Build Signatera order sets with the repeat schedule built in, push them to integrated systems, and report adoption per system to its leaders.

Ordering in the EHR removes paperwork and makes repeat testing routine.

• Clinicians dislike rigid schedules

  Keep the schedule editable.

• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source
• HiringEnterprise Strategic Accounts Manager (Chicago/Milwaukee/Madison, posted October 19, 2026): works across "Women's Health, Organ Health, Oncology, and Rare Disease" with hospital systems and IDNs on "electronic medical record (EMR) integrations, strategic contracting", and workflow standardization.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source

Build a searchable explorer: filter studies by cancer, setting, study type and endpoint, with plain-language summaries and links. Update after every congress.

The largest evidence base in MRD becomes a tool clinicians use, and a source AI assistants cite.

• Seen as promotion

  Include all studies, positive or not.

• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source
• HiringSenior Director / Director, Breast Oncology Lifecycle Management (posted October 8, 2026): will "Define value proposition and messaging framework in collaboration with commercial marketing for Natera's oncology suite of products in breast cancer", build "a roadmap to fill evidence data gaps", develop KOL engagement plans and support Medicare/MolDx and commercial payer dossiers for non-covered indications.Source
• Competitor researchRivals' own homepages: Guardant Health, "a leading precision medicine company focused on transforming patient care and conquering cancer with data"; Myriad Genetics, "hereditary cancer, prenatal, oncology and mental health genetic testing"; BillionToOne, "Prenatal Screening and Liquid Biopsy".See the research Source

Record one patient and one clinician story per major indication, publish on pages and social, and offer clips to advocacy groups.

Stories build trust and help patients raise the test with their doctor.

• Stories imply guaranteed results

  Add balanced context.

• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source
• Your websiteHomepage: tests "clinically validated in over 400 peer-reviewed publications with over 3 million patients studied", "over 16 million tests" processed and "more than 150 medical professionals on staff"; news on October 15, 2026: "Natera's Signatera(TM) MRD Test Named to TIME's List of the Best Inventions of 2026", and on October 18 ESMO 2026 presentations. The health systems page cites "3.5M+ tests performed in 2025" and "300+ of the largest health systems engaged", with Epic Aura integration and one-click ordering.Source

Publish a short decision guide: when tissue is available, when it is not, timing, and how results are used, with links to both product pages.

Natera can own the "which MRD test" question with its own two products.

• Comparison claims

  Compare only Natera's own tests.

• Your websiteNatera also offers Latitude, a tissue-free MRD test for colorectal cancer ("Expanding MRD testing to more patients with colorectal cancer"), next to the tumor-informed Signatera.Source
• Competitor researchRivals' own homepages: Guardant Health, "a leading precision medicine company focused on transforming patient care and conquering cancer with data"; Myriad Genetics, "hereditary cancer, prenatal, oncology and mental health genetic testing"; BillionToOne, "Prenatal Screening and Liquid Biopsy".See the research Source
• Your websiteSignatera page snippets (checked October 21, 2026): eight pages (the pancreatic, liver, gastroesophageal and bile duct cancer pages, patient and clinician versions) share the meta description "Signatera(TM) is a powerful, personalized assay that provides accurate monitoring for anal cancer recurrence"; the main Signatera page, the patient overview and the FAQ all describe Signatera as "a sensitive ctDNA test for colorectal cancer"; the cervical cancer patient page's main heading reads "Signatera(TM) for Pancreatic Cancer".Source

Run a monthly crawl of oncology pages for duplicate or empty descriptions, headings that do not match the URL, missing patient/clinician pairs and broken links. Fix within the month.

Small errors stop accumulating as indications launch.

• Fixes need review

  Batch them into one monthly review.

• Your websiteSignatera page snippets (checked October 21, 2026): eight pages (the pancreatic, liver, gastroesophageal and bile duct cancer pages, patient and clinician versions) share the meta description "Signatera(TM) is a powerful, personalized assay that provides accurate monitoring for anal cancer recurrence"; the main Signatera page, the patient overview and the FAQ all describe Signatera as "a sensitive ctDNA test for colorectal cancer"; the cervical cancer patient page's main heading reads "Signatera(TM) for Pancreatic Cancer".Source
• Your websiteFifteen oncology pages in the sitemap have no meta description at all, including the oncology hub, Signatera for sarcoma, ovarian, head and neck and skin cancers (patient and clinician pages), Signatera CDx, Signatera Genome, Signatera in lymphoma and both Latitude pages; several titles are generic, such as "Signatera for Sarcoma | Natera".Source

Send oncology patients the same claim-status texts and portal updates, with a link to the payment plan when a bill is issued.

Clear billing reduces calls and keeps patients willing to repeat testing.

• Texts about bills worry patients

  Lead with assistance options.

• Your websiteBilling: the women's health pricing page offers a personalized cost estimate (Panorama, Horizon, Empower, Vistara), financial assistance at "$0 to $239 per test", and interest-free payment plans of up to 12 months, and says "over 60% of patients have no out-of-pocket cost with insurance". The oncology billing page lists Signatera's Medicare indications and a phone number and email for financial assistance, but has no online cost estimate request and no payment-plan details.Source
• Your websiteSignatera patient pages: one "Speak with an expert" form serves every cancer type; the overview says the first result takes "about 3-4 weeks" and "follow-on tests usually take only 7-10 days", and that Signatera "works best when used serially over time"; the breast page walks through baseline, response, after-surgery and long-term surveillance, states Medicare coverage for stage II-IV breast cancer (neoadjuvant) and stage IIb and higher (adjuvant and recurrence monitoring), and features patient stories from Danielle and Anj.Source